PEC-Direct Islet Cell Replacement Therapy

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePEC-Direct Islet Cell Replacement Therapy
Drug Alias NameVC-02 Combination ProductPEC-DirectPEC-01VC-02
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Pancreatic islet cell therapy
Mechanisms of ActionPancreatic beta cell replacements
TargetsNot applicable
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesViacyte Inc
China Registration ClassN/A

Develop Information

Active CompaniesViacyte IncVertex Pharmaceuticals Incorporated
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A